H.C. Wainwright downgraded iTeos Therapeutics (ITOS) to Neutral from Buy without a price target after GSK decided to terminate the development of belrestotug, marking the end of clinical development of all Fc-competent anti-TIGIT antibodies. The two partners are discontinuing all belrestotug-related studies, the analyst tells investors in a research note. As a result, H.C. Wainwright moved to the sidelines on shares of iTeos Therapeutics.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITOS:
- iTeos Therapeutics downgraded to Market Perform from Outperform at Leerink
- Strategic Shift and Strong Financials Position iTeos Therapeutics for Growth
- iTeos Therapeutics downgraded to Neutral at JPMorgan after TIGIT program ended
- iTeos Therapeutics downgraded to Neutral from Overweight at JPMorgan
- iTeos Therapeutics Ends Collaboration with GSK